Is IL-6 a key cytokine target for therapy in COVID-19?

Jones, Simon A; Hunter, Christopher A

Jones, Simon A; Hunter, Christopher A.

Jones SA; Division of Infection & Immunity, The School of Medicine, Cardiff University, Cardiff, Wales, UK. jonessa@cardiff.ac.uk.
Hunter CA; Systems Immunity Research Institute, Cardiff University, Cardiff, Wales, UK. jonessa@cardiff.ac.uk.

Nat Rev Immunol ; 21(6): 337-339, 2021 06.

Article in English | MEDLINE | ID: covidwho-1182836

Subject(s)

COVID-19 Drug Treatment; COVID-19/immunology; Cytokine Release Syndrome/drug therapy; Cytokine Release Syndrome/immunology; Interleukin-6/antagonists & inhibitors; SARS-CoV-2; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/therapeutic use; COVID-19/complications; Cytokine Release Syndrome/etiology; Cytokines/antagonists & inhibitors; Humans; Interleukin-6/blood; Receptors, Interleukin-6/antagonists & inhibitors; Severity of Illness Index; Signal Transduction/drug effects; Signal Transduction/immunology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interleukin-6 / Cytokine Release Syndrome / SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Nat Rev Immunol Journal subject: Allergy and Immunology Year: 2021 Document Type: Article Affiliation country: S41577-021-00553-8

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google